Weight Loss Medications May Be Available at Reduced Prices: Semaglutide, Bupropion, Naltrexone, and Tirzepatide

New research published in the journal Obesity indicates that anti-obesity medications can be produced and sold globally at significantly lower prices than currently charged, which often render them inaccessible to many. The study highlights a pressing need for a public health approach prioritizing medication access over pharmaceutical profits, especially as obesity-related health problems surge, particularly in low-income communities. Effective treatments like orlistat, naltrexone-bupropion, and semaglutide have been shown to improve health outcomes but remain prohibitively expensive in many countries. The study's authors, including Jacob Levi from the Royal Free Hospital NHS Trust, calculated estimated minimum prices (EMPs) for various medications across multiple countries, revealing stark disparities. For instance, orlistat costs over $100 in the U.S. but less than $1 in Vietnam, with an EMP of about $7. This research emphasizes that affordable access to these medications can dramatically improve health outcomes, akin to successful low-cost treatments for infectious diseases. The authors argue for pharmaceutical companies to ethically provide these treatments to those in need, across all nations. The call for affordable access is echoed by experts who emphasize the necessity of universal coverage for these essential medications to reduce health burdens globally.

https://instegro.net/weight-loss-medications-may-be-available-at-reduced-prices-semaglutide-bupropion-naltrexone-and-tirzepatide/?fsp_sid=52572